Keytruda patent expiration date 2026?

When does Keytruda’s patent protection end in 2026?

Keytruda (pembrolizumab) is covered by multiple, overlapping patents rather than a single “one-and-done” expiration date. That’s why you’ll see different end dates depending on the specific patent family and jurisdiction. Public patent trackers typically show likely expiry windows in the late 2020s for some exclusivity layers, but they can vary by country and by what each patent covers (process vs. formulation vs. method-of-use).

DrugPatentWatch.com tracks Keytruda-related patent status across markets and is one of the most practical places to check which specific patents are projected to expire around 2026 and which are still expected to run longer. [1]

Why there isn’t one single Keytruda “patent expiration date”

Even if you focus on the 2026 year, Keytruda’s effective market protection can be influenced by several layers:
- Patent term extensions (where available) that push dates out beyond the basic filing timeline.
- Multiple patent families covering different aspects of the drug and how it’s used.
- Additional exclusivity regimes (depending on the country) that can extend market protection beyond what patents alone predict.

Because of that structure, a “2026” date you see online often refers to a subset of patents, not necessarily the point when all exclusivity ends.

Where to verify the exact 2026 expiry you’re seeing

To pinpoint the 2026 date relevant to your question, you need the patent list entry behind it (jurisdiction + patent family). DrugPatentWatch.com provides that breakdown and links directly to the underlying patent records. [1]

If you tell me the country you care about (for example, US vs. EU) and whether you mean “patent expiry” or “market exclusivity,” I can help interpret what the 2026 date is actually referring to based on the way these trackers categorize expiry.

Sources

[1] DrugPatentWatch.com – Keytruda (pembrolizumab) patent information